Cullinan oncology to present new preclinical data for cln-619 and cln-617 at the 2023 american association for cancer research annual meeting

Cln-619 is a mica/b directed humanized igg1 antibody being studied in a global phase 1 clinical trial in patients with advanced solid tumors. initial clinical data from the ongoing trial is on-track to be released mid-2023.

CGEM Ratings Summary

CGEM Quant Ranking